Skip to main content
. 2024 Mar 9;75:103713. doi: 10.1016/j.breast.2024.103713

Fig. 4.

Fig. 4

Rate of trials per drug class allowing men inclusion per protocol criteria Abbreviations: ICI: immune checkpoint inhibitors; PARP-i: Poly (ADP-ribose) polymerase inhibitors; ADC: antibody drug conjugate; PI3K/AKT/mTOR-i: Phosphoinositide 3-kinases/AKT/mammalian target of rapamycin inhibitors; CDK 4/6-i: cyclin-dependent kinase 4 and 6 inhibitors; ET: endocrine therapy; CT: chemotherapy.